

To: [redacted] <[redacted]@minvws.nl>
From: [redacted]
Sent: Tue 3/31/2020 2:53:03 PM
Subject: FW: joint procurement
Received: Tue 3/31/2020 2:53:03 PM

Van: [redacted] <[redacted]@rivm.nl>

Verzonden: dinsdag 31 maart 2020 16:49

Aan: [redacted]@ec.europa.eu

CC: [redacted] <[redacted]@minvws.nl>; [redacted] <[redacted]@minvws.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>

Onderwerp: joint procurement

dear [redacted]

you asked us about possible joint procurement of investigational therapeutics for COVID-19.

We do not know the outcomes of the studies on remdesivir, but in cases these outcomes show that this antiviral is efficacious and safe, we will be interested in a joint procurement procedure.

It will be difficult to predict the course of the epidemic in the Netherlands after May.

We foresee a rise in the next 8 weeks, and by that time possibly the first data on remdesivir will become available and we may be able to make a prediction of needed doses.

That is the only drug we will be interested in at this moment.

kind regards,

[redacted]

infectious disease specialist

RIVM the Netherlands

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en Committed to *health and sustainability*